Alfasigma claims early FDA nod for ex-GSK liver drug Alfasigma has claimed the first approval, in the US, for linerixibat, a drug for liver disease PBC licensed from GSK for $690m a few days ago.

The #FDA has approved #Alfasigma's #primarybiliarycholangitis (PBC) therapy #linerixibat, just days after the company licensed it from #GSK in a deal worth up to $690 million.

pharmaphorum.com/news/alfasig...

Linerixibat Significantly Reduces Pruritus in PBC The GLISTEN trial tested the safety, efficacy, and impact of linerixibat on patients’ health-related quality of life compared with a placebo.

#Linerixibat significantly reduces #Pruritus compared with placebo in patients with #PrimaryBiliaryCholangitis (PBC), according to results from the phase 3 clinical GLISTEN trial (#NCT04950127). Published in @lancetgastrohep.bsky.social

Read here: https://bit.ly/4oZ6tKk

#RareDisease #ClinicalTrial

IBAT inhibitor linerixibat shows rapid cholestatic pruritus reduction Treatment with linerixibat significantly and rapidly reduces itch in people with primary biliary cholangitis.

From #UEGWeek 2025 - Treatment with #linerixibat significantly and rapidly reduces itch in people with primary biliary #cholangitis.

Full story 👉 buff.ly/JkyKnxp

#MedNews

Chronic Pruritus Market Set for Significant Growth with Emerging Therapies and Innovative Treatments The chronic pruritus market is projected to experience a robust CAGR of 8.6% between 2020 and 2034, driven by innovative therapies like Dupilumab and others.

Chronic Pruritus Market Set for Significant Growth with Emerging Therapies and Innovative Treatments #None #Chronic_Pruritus #Dupilumab #Linerixibat